Merck & Co. (MRK)
(Delayed Data from NYSE)
$113.69 USD
+0.60 (0.53%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $113.60 -0.09 (-0.08%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$113.69 USD
+0.60 (0.53%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $113.60 -0.09 (-0.08%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth B Momentum B VGM
Zacks News
Bristol Myers' (BMY) Opdivo-Yervoy Combo Gets Positive CHMP Opinion
by Zacks Equity Research
Bristol Myers' (BMY) Opdivo in combination with Yervoy gets positive CHMP recommendation by the EMA for an additional indication.
TOTAL (TOT) Signs 10-Year Deal With Merck to Sell Clean Power
by Zacks Equity Research
TOTAL (TOT) signs a 10-year deal with Merck to sell clean energy to the latter. TOTAL is working to scale up renewable energy generation capability by adding new wind and solar assets.
The Zacks Analyst Blog Highlights: Sanofi, GlaxoSmithKline, Pfizer, Eli Lilly and Merck
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Sanofi, GlaxoSmithKline, Pfizer, Eli Lilly and Merck
Bristol Myers (BMY) Gets FDA Nod for Another Opdivo Indication
by Zacks Equity Research
Bristol Myers (BMY) gets FDA approval for Opdivo (injection for intravenous use) for adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer.
Merck's (MRK) Pneumococcal Vaccine Succeeds in Pediatric Trials
by Zacks Equity Research
Merck's (MRK) 15-valent pneumococcal conjugate vaccine candidate, V114, demonstrates comparable immunogenicity and safety compared to a lower valency vaccine in infants and children.
Pharma Stock Roundup: GSK/SNY COVID-19 Vaccine Data, PFE's New EU Supply Deal
by Kinjel Shah
Sanofi (SNY) and Glaxo's (GSK) COVID-19 vaccine shows strong antibody response in phase II. Lilly's fifth phase III study on tirzepatide meets all key endpoints
Merck (MRK) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Corcept's (CORT) Lead Drug Korlym Aids Growth Amid Competition
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug, Korlym, is making good progress. Other pipeline candidates are advancing as well. However, sole dependence on Korlym for growth remains an overhang.
The Zacks Analyst Blog Highlights: JPMorgan, Home Depot, Merck, T-Mobile US and Twilio
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JPMorgan, Home Depot, Merck, T-Mobile US and Twilio
Merck (MRK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $78.41, marking a +0.81% move from the previous day.
Top Research Reports for JPMorgan, Home Depot & Merck
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase (JPM), The Home Depot (HD), and Merck (MRK).
Moderna (MRNA) Beats on Q1 Earnings, Ups Vaccine Sales View
by Zacks Equity Research
Moderna (MRNA) reports first profitable quarter on the back of its success with COVID-19 vaccine. The number of COVID-19 vaccine doses delivered in the first quarter add up to 102 million.
Corcept's (CORT) Q1 Earnings Miss Estimates, Revenues Fall Y/Y
by Zacks Equity Research
Corcept (CORT) reports wider-than-expected loss in the first quarter of 2021, with its revenues also missing estimates.
Iovance (IOVA) Q1 Earnings Miss Estimates, Pipeline in Focus
by Zacks Equity Research
Iovance's (IOVA) first-quarter earnings lag estimates. The company is progressing well in terms of development of its lead pipeline candidate.
Esperion (ESPR) Q1 Earnings Miss, Lower Drug Price Hits Sales
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports dismal first-quarter results as it misses estimates for earnings and sales. Stock down.
Google, Travelzoo, Moderna, Merck and Milestone Pharmaceuticals highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Google, Travelzoo, Moderna, Merck and Milestone Pharmaceuticals highlighted as Zacks Bull and Bear of the Day
Pfizer's (PFE) Key Drugs Likely to Drive Its Q1 Earnings
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, and revenues from COVID-19 vaccine are likely to have driven sales in the first quarter.
Moderna (MRNA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors are likely to focus on any updated outlook for Modena's (MRNA) authorized coronavirus vaccine and developmental progress with new COVID-19 vaccine candidate on the first-quarter earrings call.
3 Big Drugmaker Stocks to Watch Out For Amid Pandemic Woes
by Kinjel Shah
Most Large Cap Pharmaceuticals industry players' Q1 results have been disappointing. Launch of COVID-19 vaccines and medicines is playing a crucial role in driving the industry. PFE, JNJ and AZN may prove to be good additions to your portfolio.
The Zacks Analyst Blog Highlights: Eli Lilly, Merck, GlaxoSmithKline, Novartis and Johnson & Johnson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Merck, GlaxoSmithKline, Novartis and Johnson & Johnson
Pharma Stock Roundup: Big Drugmakers' Q1 Earnings, Resumption of JNJ US COVID-19 Jabs
by Kinjel Shah
Several large drugmakers announce Q1 earnings. Many miss estimates for both earnings and sales. J&J (JNJ) resumes COVID-19 vaccination in the United States.
AstraZeneca (AZN) Q1 Earnings Top, COVID-19 Vaccine Adds $275M
by Zacks Equity Research
AstraZeneca (AZN) surpasses first-quarter estimates on both counts. Stock up in pre-market.
Gilead (GILD) Beats on Q1 Earnings, HIV Sales Decline
by Zacks Equity Research
Gilead (GILD) reports mixed results for the first quarter as the ongoing pandemic adversely impacted core HIV segment sales.
Company News for Apr 30, 2021
by Zacks Equity Research
Companies in The News Are: MRK,KHC,SO,NOC
Merck (MRK) Q1 Earnings & Sales Miss, COVID-19 Hurts Vaccines
by Kinjel Shah
Merck (MRK) misses Q1 estimates for earnings and sales. Stock down in pre-market.